Investment Rating - The report does not explicitly provide an investment rating for the automotive industry or specific companies within it [26]. Core Insights - The year-end sales data for major automakers indicates a significant divergence in performance, with the typical "year-end tailwind" being weaker than in previous years. The phase-out of the "two-new" subsidy policies is contributing to a trend of slowing or declining sales growth [8][9]. - BYD's November sales were 480,000 units, down 5% year-on-year but up 9% month-on-month, primarily due to weaker domestic demand. Domestic sales were 348,000 units, down 27% year-on-year. Cumulative sales from January to November reached 4.18 million units, an 11% increase year-on-year [9][10]. - Geely's November sales reached 310,000 units, a 24% year-on-year increase, with cumulative sales of 2.79 million units, up 42% year-on-year, putting its annual target of 3 million units within reach. NEV sales for Geely in November were 188,000 units, a 53% year-on-year increase [9][10]. - Leapmotor exceeded 70,000 units in November, marking a 75% year-on-year increase, with cumulative deliveries reaching 536,000 units, surpassing its annual target ahead of schedule [10][11]. - Xiaomi Auto delivered over 40,000 units in November, maintaining this level for three consecutive months, and raised its full-year delivery outlook to over 400,000 units [12]. - Li Auto's November deliveries were 33,000 units, down 32% year-on-year, with cumulative deliveries of 362,000 units, an 18% decrease year-on-year [13]. - NIO's November sales were 36,000 units, a 76% year-on-year increase, but cumulative deliveries totaled 278,000 units, indicating challenges in achieving profitability in Q4 [14][15]. Summary by Sections Sales Performance - BYD's November sales were 480,000 units, with domestic sales at 348,000 units, reflecting a significant year-on-year decline [9][10]. - Geely's sales performance showed strong growth, particularly in NEVs, with a notable increase in overseas exports [9][10]. - Leapmotor and Xiaomi Auto demonstrated robust sales growth, exceeding their targets [10][12]. Market Dynamics - The automotive market is experiencing a reshuffling of sales rankings, with leading new energy vehicle (NEV) players facing slowing growth [10][11]. - The competitive landscape is intensifying, with companies needing to balance volume and profitability as subsidies phase out [15].

Investment Rating - The report assigns an "Outperform" rating to the company, with a target price of 40.35 HKD based on a 15x PE for FY2026 [5][13]. Core Insights - The company is experiencing improved same-store sales, particularly in Mainland China, and is accelerating its overseas expansion efforts [15]. - Rising gold prices and an increased share of priced jewelry are driving improvements in gross profit margin (GPM), which reached 34.7% in FY26H1, up 2.0 percentage points year-on-year [3][16]. - The company plans to open 20 new overseas stores in FY26 and aims to enter at least three new countries and add 50 overseas stores over the next three years [15]. Financial Summary - For FY26H1, total revenue was 6.84 billion HKD, a year-on-year increase of 25.6%, with gross profit of 2.37 billion HKD, up 33.2% [14]. - The net profit attributable to shareholders for FY26H1 was 619 million HKD, reflecting a 42.5% year-on-year increase, with a net profit margin of 8.8% [14]. - The company forecasts total revenue for FY2026 to be 15.56 billion HKD, with a projected net profit of 1.58 billion HKD [4][5].

[Table_Title] 研究报告 Research Report 1 Dec 2025 寇媛媛 Yuanyuan Kou 陈芳园 Ashley Chen yy.kou@htisec.com ashley.fy.chen@htisec.com [Table_yemei1] 热点速评 Flash Analysis [Table_summary] (Please see APPENDIX 1 for English summary) 事件：2025 年 11 月 26 日，周大福珠宝集团发布 2026 财年中期业绩报告并召开业绩会。 周大福 Chow Tai Fook (1929 HK) 1HFY26 同店与 ASP 改善，管理层维持 FY26 收入指引 Same-Store Sales and ASP Improve in 1HFY26, Management Maintains FY26 Revenue Guidance 1HFY26收入小幅承压，公司通过费用优化实现营运利润率与股东回报双稳健。周大福自FY2025起变更了会计准则， 在现行会计结构下，周大福的黄金借贷公允价值变动已从"销售成本"重分类至"其 ...

Market Performance - The Black Friday kickoff has significantly boosted overseas consumption, leading to a positive sentiment in the A/H-share consumer sectors[1] - Weekly performance of various sectors showed strong growth, with the gaming sector leading at 6.9%, followed by overseas sportswear at 6.8% and overseas cosmetics at 4.1%[11] - Year-to-date performance highlights jewelry as the top performer with a 133.9% increase, while overseas sportswear has seen a decline of 15.4%[11] Sector Analysis - The overseas sportswear sector is expected to have a PE ratio of 30.2x in 2025, which is 57% of the average PE over the past five years[15] - The domestic sportswear sector's expected PE is 14.7x, representing 77% of its historical average[15] - The gaming sector's expected PE is 17.2x, which is only 28% of its five-year average, indicating potential undervaluation[15] Company Highlights - Notable stock performances include Sands China up 11.2% and MGM China up 9.1%, driven by positive trends in Macau's gaming revenue[14] - Lululemon's stock surged by 9.5% due to strong demand for new winter apparel, with expectations for a positive Q3 2025 earnings report[14] - E.L.F. Beauty's stock rose by 8.7% following favorable analyst ratings and improved sales trends[14] Consumer Sentiment - The retail sector saw a 3.6% increase, with Walmart and Target benefiting from the Black Friday shopping season[14] - The luxury goods sector increased by 2.5%, supported by expectations of strong performance during the holiday shopping season despite high valuation levels[14] - Domestic cosmetics stocks rose by 2.2%, with significant growth reported by companies like Shiseido and Marubi[14]

Investment Rating - The report maintains an "Outperform" rating for JD Health International [1][2][17]. Core Insights - JD Health International continues to show strong revenue and profit growth, with Q3 2025 revenue reaching RMB 17.12 billion, a year-on-year increase of 28.7%, and net profit of RMB 1.84 billion, up 97.2% year-on-year [3][13][14]. - The company has raised its full-year revenue growth guidance to approximately 22.0% from the previous 20.0%, and adjusted profit target to RMB 6.20 billion from RMB 5.60 billion, reflecting strong Q3 performance [4][15]. - The report highlights the company's effective marketing investments and improved bargaining power in the pharmaceutical category as key drivers of growth [14][16]. Financial Performance Summary - For FY 2025, revenue is projected to be RMB 71.05 billion, representing a 22.1% year-on-year growth, while adjusted profit is expected to be RMB 6.21 billion, a 30% increase [5][16]. - The gross profit margin is expected to improve to 24.6% in FY 2025, with a net profit margin of 7.5% [10][16]. - The company’s DCF valuation predicts an equity value of HKD 227.44 billion, corresponding to a target share price of HKD 71.07, reflecting a 4.3% increase in target price [5][17].

Investment Rating - The report does not explicitly state the investment rating for Bosideng International Holdings Core Insights - The principal brand of Bosideng drove growth in 1H25, while other business segments contracted year-on-year [1][3] - Total operating revenue for 1H25 was RMB 8.93 billion, a year-on-year increase of 1.4%, with profit attributable to owners rising by 5.3% to RMB 1.19 billion [2][8] - The gross profit margin for 1H25 was 50.0%, reflecting a slight year-on-year increase of 0.2 percentage points but a decrease of 7.3 percentage points from the previous half-year [2][8] - The company optimized inventory turnover days to 178 days, down from 189 days in the same period last year [2][8] Revenue Breakdown - Revenue from the Bosideng brand grew by 8.3% to RMB 6.57 billion, accounting for 73.6% of total revenue [3][9] - The ODM business saw a revenue decline of 11.7% year-on-year, while womenswear revenue decreased by 18.6% to RMB 250 million [3][9] - The diversified clothing business, primarily school uniforms, recorded a significant revenue drop of 45.3% to RMB 64 million [3][9] - Raw material sales revenue increased by 22.8% year-on-year, indicating strong demand in that segment [3][9] Operational Efficiency - The company employs a smart distribution center and integrated inventory management to enhance sales growth and manage inventory effectively [4][10] - The operational model allows for rapid response to market changes, contributing to a significant reduction in inventory turnover days [4][10] - AI technology is being utilized to drive apparel design and improve online operations, significantly reducing operational costs [4][10] Marketing Strategy - The company focuses on high-quality store openings in landmark commercial complexes to maximize brand exposure [5][12] - A refined operation model of "unique design per store, specific strategy per store" is being implemented [5][12] - During the Double Eleven shopping festival, the company achieved growth with lighter discounts, ranking first in several e-commerce platforms [5][12]

Investment Rating - The investment rating for the essential consumer goods sector is "Outperform" for multiple companies including Kweichow Moutai, Wuliangye, and Yili [1] Core Insights - In November 2025, four out of eight monitored essential consumer sectors showed positive growth, while four experienced negative growth, with the growth sectors being condiments, frozen foods, soft drinks, and catering services [29] - The overall growth rates across all sectors have slowed compared to the previous month, attributed to macroeconomic conditions, structural industry challenges, and seasonal factors [29] Subsector Summaries Mid-to-High-End and Above Baijiu - Revenue for the mid-to-high-end and premium baijiu sector in November was RMB 24 billion, down 13.0% year-on-year, with cumulative revenue from January to November at RMB 349.2 billion, a decline of 6.2% [30] - The market is experiencing simultaneous declines in both volume and price, with a conservative consumer spending trend [30] Mass-Market and Below Baijiu - Revenue for the mass-market and lower-tier baijiu industry reached RMB 18.9 billion in November, marking a 3.3% year-on-year decline, with cumulative revenue from January to November totaling RMB 180.9 billion, down 8.5% [30] - The production of baijiu in October was 276,000 kiloliters, down 18.3% year-on-year, indicating a challenging market environment [30] Beer - The domestic beer industry generated revenue of RMB 9.9 billion in November, a 2.0% year-on-year decline, with cumulative revenue from January to November at RMB 162.6 billion, representing a 0.2% year-on-year increase [31] - Seasonal demand has decreased due to a nationwide temperature drop, leading to subdued overall demand [31] Condiments - The condiments sector reported revenue of RMB 418 billion in November, a year-on-year increase of 0.8%, with cumulative revenue from January to November at RMB 4,129 billion, up 1.3% [18] Frozen Foods - The frozen foods sector achieved revenue of RMB 81.6 billion in November, a year-on-year increase of 4.0%, with cumulative revenue from January to November at RMB 964 billion, up 2.2% [22] Soft Drinks - Revenue for the soft drinks sector was RMB 388 billion in November, a year-on-year increase of 2.1%, with cumulative revenue from January to November at RMB 6,583 billion, up 4.1% [24] Catering - The catering industry reported revenue of RMB 130.4 billion in November, a year-on-year increase of 0.3%, with cumulative revenue from January to November at RMB 1,607 billion, down 0.7% [26]

Investment Rating - The report assigns an "Outperform" rating to the company, forecasting EPS for 2025, 2026, and 2027 to be RMB 0.37, RMB 0.51, and RMB 0.61 respectively, with a target price set at RMB 18.34 based on a moderate PB premium of 0.65x for 2025 [3][10]. Core Insights - The company has successfully launched the first consumer holding real estate ABS in China, marking a significant milestone in innovative financing. This ABS, managed by Sinolink Securities, has an issuance size of RMB 616 million and a term of approximately 25 years [3][10]. - The company reported a total commercial operation revenue of approximately RMB 10.51 billion for the first nine months of 2025, reflecting a year-on-year increase of 10.82% and maintaining a high occupancy rate of 97.7% [3][10]. - The company has expanded its presence to 143 cities with 205 Wuyue Plazas, achieving a total foot traffic of 950 million, which is a 16.0% increase year-on-year, and a membership base of 49.17 million [3][10]. - The company has made significant strides in both domestic and foreign financing, successfully issuing USD 300 million in senior unsecured bonds and USD 160 million in senior secured notes, alongside medium-term notes in the domestic market [3][10]. Financial Summary - The company’s total revenue for 2023 is projected at RMB 119.17 billion, with a decline expected in subsequent years, reaching RMB 58.48 billion in 2025, a decrease of 34.3% [2][4]. - Net profit attributable to the parent company is forecasted to be RMB 737 million in 2023, with a gradual increase to RMB 1.38 billion by 2027 [2][4]. - The company’s net asset return is expected to improve from 1.2% in 2023 to 2.0% in 2027, indicating a positive trend in profitability [2][4].

短期业绩波动，不改长期趋势 天孚通信(300394) ——三季报业绩点评 股票研究 /[Table_Date] 2025.12.01 2025-12-01 电信运营 [Table_Industry] /信息技术 本报告导读： 下调盈利预测和目标价，维持增持评级；业绩略低预期，不改需求向好；盈利能力 保持稳定，持续投入扩产。 投资要点： 风险提示：行业需求低于预期，行业竞争更加恶劣。 | [Table_Finance] 财务摘要(百万元) | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入 | 1,939 | 3,252 | 6,090 | 9,074 | 10,864 | | (+/-)% | 62.0% | 67.7% | 87.3% | 49.0% | 19.7% | | 净利润(归母) | 730 | 1,344 | 2,254 | 3,328 | 3,999 | | (+/-)% | 81.1% | 84.1% | 67.8% | 47.6% | 20.2% | | 每股净收益( ...

Investment Rating - The report maintains an "Outperform" rating for A-Shares including Jiangsu Heng Rui Medicine, Sichuan Kelun Pharmaceutical, Huadong Medicine, Jiangsu Nhwa Pharmaceutical, Xiamen Amoytop Biotech, Zhejiang Jingxin Pharmaceutical, Innovent Biologics, WuXi AppTec, Hangzhou Tigermed Consulting, Lepu Medical, and APT Medical [2][4][29] - The report also maintains an "Outperform" rating for H-Shares including Hansoh Pharmaceutical Group, 3SBio, PATEO, Akeso, and related targets such as Innovent Biologics and WuXi AppTec (H-Shares) [2][7][29] Core Insights - The report continues to recommend the innovative drug and device industry chain [1][2] - In November 2025, the pharmaceutical sector underperformed the broader market, with the SW Pharma Bio index falling by 3.6% compared to a 1.7% drop in the SHCOMP [2][10] - The premium of the pharmaceutical sector to all A-Shares is currently at a normal level of 72.6% as of the end of November 2025 [17][22] Summary by Sections A-Shares Performance - The report highlights the A-Shares that are recommended for investment, maintaining an "Outperform" rating for several companies, including Jiangsu Heng Rui Medicine and Sichuan Kelun Pharmaceutical, among others [4][5] - The report notes that the pharmaceutical sector's performance was ranked 23rd among Shenwan's first-level industries in November 2025 [10][12] H-Shares Performance - The report indicates that the H-Shares pharmaceutical sector performed in line with the market, with the Hang Seng Healthcare index down by 0.1% and the biotech sector up by 0.4% in November 2025 [2][23] - Top gainers in the H-Shares market included Laekna, Inc. (+40%) and Clover Biopharmaceuticals, Ltd. (+22%) [23] U.S. Market Performance - The U.S. pharmaceutical sector outperformed the broader market in November 2025, with the S&P Healthcare Select Sector rising by 9.1% compared to a 0.1% increase in the S&P 500 [23]